Royalty Report: Drugs, Drug Discovery – Collection: 367346

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 5

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5

Primary Industries

  • Drugs
  • Drug Discovery

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 367346

License Grant
Licensor grants a worldwide, exclusive license, with the right to grant sublicenses, under the Licensor Licensed Technology to develop, make, have made, import, export, use, sell, offer for sale and have sold potential products and commercial products in the field.

This agreement includes a non-exclusive grant back from Licensee to Licensor.

License Property
Licensor has proprietary technology useful for attaching PEG or poly( ethylene) glycol-based molecules to pharmaceutical compounds, and is engaged in the business of performing research in relation to Reagents and Conjugates and manufacturing bulk quantities of Reagents used in the manufacture of pharmaceutical products.

Licensor Core Technology means
— the composition of Reagents, but specifically excluding those Reagents disclosed in the Licensee VWF Patents that are not Licensor Proprietary Reagents on the effective date;
— methods of using Reagents, but specifically excluding those methods disclosed in the Licensee VWF Patents that are not Licensor Proprietary Methods on the effective date;
— methods of making, processing, analyzing or characterizing Reagents (including selected reagents);
— methods of attaching one or more Reagents, including selected reagents, to or associating one or more Reagents, including selected reagents, with or to any therapeutic agent, including a therapeutic agent, but specifically excluding those methods disclosed in the Licensee VWF patents that are not Licensor Proprietary Methods on the effective date;
— methods of directing or controlling the point of attachment of one or more reagents, including selected reagents, to or associating one or more reagents {including selected reagents) with any therapeutic agent (including a therapeutic agent), but specifically excluding such · methods disclosed in the Licensee VWF patents that are not Licensor Proprietary Methods on the effective date;
— the composition of any product (including conjugates, potential products and commercial products) obtained by attaching or associating one or more reagents, including selected reagents, by Pegylation to or with any therapeutic agent (including a therapeutic agent) other than those compositions defined within, that is a Licensee Proprietary Conjugate, or that falls within the scope of jointly owned technology; and
— methods of making, formulating, combining, processing, using, analyzing or characterizing 2 or more reagents (including selected reagents) in combination.

Potential Product means any chemical entity resulting from attachment of any therapeutic agent to a selected reagent by means of Pegylation that is selected by the Research Committee or any product using Pegylation to extend or otherwise improve the half-life of Factor VII or Factor VIII, whether by using Pegylation technology directly with Factor VII or Factor VIII, or by means of the Pegylation of Von Willebrands Factor (e.g., indirectly using Von Willebrands Factor as a carrier for Factor VIII).

Field of Use
The field means Pegylated Von Willebrands Factor, either for use alone for the treatment of Von Willebrands disease or as a carrier for Factor VIII, in the treatment of Hemophilia A, or Pegylated Factor VIII or Pegylated Factor VII for the treatment of Hemophilia A.
Von Willebrand disease (VWD) is a blood disorder in which the blood does not clot properly. Blood contains many proteins that help the blood clot when needed. One of these proteins is called von Willebrand factor (VWF). People with VWD either have a low level of VWF in their blood or the VWF protein doesn’t work the way it should.

IPSCIO Record ID: 282931

License Grant
Licensor agrees to grant and hereby grants to Company a worldwide, exclusive, royalty-bearing license, with the right to grant sublicenses, in the Licensor licensed technology solely to use selected Reagent for and to research, develop, make, have made, import, use, offer for sale and sell selected product in the field and in the territory.
License Property
Selected Product means the chemical entity resulting from attachment of the Therapeutic Agent to the Selected Reagent by means of Pegylation, as formulated, packaged and sold in finished form.

Selected Reagent means the Reagent that is selected by the Research Committee pursuant to the Research Program to be attached to the Therapeutic Agent by means of Pegylation.

Therapeutic Agent means human recombinant butyrylcholinesterase (BChE) having the amino acid sequence or having an amino acidsequence with 86% sequence identity to such human BChE sequence or a fragment of such a BChE and in each case which has activity of human recombinant butyrylcholinesterase (BChE).

Reagent means a PEG derivative used in the manufacture of a pharmaceutical or diagnostic product or medical device.

PEG means poly(ethylene) glycol or a derivative thereof.

Pegylation, with correlative meanings 'Pegylated' or to 'Peglate', means covalent chemical bonding of any Reagent (including Selected Reagent and including covalent chemical bonding through linking groups) with or to another material or materials. Such materials include, without limitation, proteins, peptides, oligonucleotides, other biomolecules, small molecules, therapeutic agents (including Therapeutic Agent), diagnostic agents, imaging agents and detectable labels. Additional materials that may be Pegylated include without limitation, polymers, liposomes, films, chemical separation and purification surfaces, solid supports, metal/metal oxide surfaces and other surfaces such as, by way of example but not limitation, those on implanted devices, and equipment, where a Reagent is covalently chemically bonded to one or more reactive molecules on the surface of such device or equipment. 'Pegylation' shall include the synthesis, derivatization, characterization, and modification of PEG for such purposes, together with the synthesis, derivatization, characterization, and modification of the raw materials and intermediates for the manufacture of Reagents (including Selected Reagent) or products (including Selected Product) incorporating such Reagent by means of covalent chemical bonding, and all methods of making and using each and all of the foregoing.

Patent Application means an application for letters patent, including a provisional application, converted provisional application, continuation application, a continued prosecution application, a continuation-in-part application, a divisional application, a re-examination application, and a reissue application (and in each case any foreign counterpart thereto).

Field of Use
Field means the treatment, prevention or diagnosis of human diseases, disorders or conditions (other than Hemophilia A).

IPSCIO Record ID: 369275

License Grant
Korean Licensor hereby grants to Licensee, after the Phase I Development Period, an exclusive, sublicenseable, royalty-bearing license, under the Licensor Technology, to conduct Clinical Development and Manufacturing Development, to Manufacture and to Commercialize Products in the Field in the Territory. Licensee shall not, and shall not permit any of its Affiliates or sublicensees to, use or practice any Licensor Technology outside the scope of the license granted to it under this Agreement.
License Property
Product means any product containing any Compound, including the Lead Candidate.

Compound means Licensees CB 2679d and Licensees other novel variants of human factor IX ('FIX'), defined in the Agreement whether in existence as of the Effective Date or anytime thereafter during the Term.

Lead Candidate means any Product containing the Licensees FIX variant CB 2679d Compound or, any replacement Compound selected by the JSC pursuant to this Agreement.

Licensor Technology means the Licensor Know-How and the Licensor Patents.

Field of Use
The Parties have formed a strategic collaboration to develop Licensee's next-generation Factor IX development candidate FIX-NG (CB 2679d) for the prevention and treatment of bleeding in hemophilia B patients.

CB 2679d/ISU 304 is a next-generation Factor IX drug for the on-demand and prophylactic treatment of patients with hemophilia B, a chronic disease caused by a genetic deficiency in coagulation Factor IX.
Hemophilia B is a rare genetic bleeding disorder in which affected individuals have insufficient levels of a blood protein called factor IX. Factor IX is a clotting factor. Clotting factors are specialized proteins needed for blood clotting, the process by which blood seals a wound to stop bleeding and promote healing.

CB 2679d/ISU 304 has demonstrated duration of action in vivo in preclinical models of bleeding and coagulation correction approximately 8 times longer than BeneFIX®, the currently marketed Factor IX therapeutic, and 2-3 times longer than Alprolix, Biogen Idec’s approved Factor IX-Fc fusion protein.

IPSCIO Record ID: 372477

License Grant
Licensor hereby grants to Licensee, for the term of this agreement, an exclusive license (with the right to grant sublicenses) under the Licensed Technology to make and have made (including through use of the Reagent), develop, use, import, offer for sale and sell the Product in the Territory.

Licensor shall grant to Licensee, until the last-to-expire valid patent claim of Enzon Patents, a sole license (with the right to grant sublicenses) under those rights Licensor has to the Enzon Patents, solely to develop, make, have made, use, import, offer for sale and sell in the territory that version of the Product that incorporates Reagent as covalently bonded to the Therapeutic Agent and has a branched backbone structure with two (2) arms and a molecular weight of 40K daltons. Such license shall be subject to the retained rights of Enzon and the Enzon affiliates to practice all the inventions described and claimed in the Enzon Patents for the conduct of research and development (such purposes not including in connection with human clinical trials) of pharmaceutical products that it is developing either itself, with its affiliate, or in conjunction with a third party.

Licensor shall grant to Licensee, for the sole purpose of, and with respect to and only with respect to, the manufacture, use, sale, offer for sale, and importation in the territory of that version of the Product that uses Reagent to covalently bond to the Active Molecule in the Therapeutic Agent and has a branched backbone structure with two (2) arms and a molecular weight of 40K daltons, a non-exclusive license under those rights Licensor has

License Property
US Patent 5,650,234 – Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces

US Patent 5,932,462 – Multiarmed, monofunctional, polymer for coupling to molecules and surfaces

Product shall mean Licensee’s lead compound known as of the Effective Date as El0030, the structure of which is set forth in the agreement and which is, a product produced by linking the Therapeutic Agent to the Reagent by means of Pegylation.

EI0030 is a pegylated aptamer containing 32 monomeric units (32-mer) arranged as a linear sequence of three oligonucleotide segments connected by non-nucleotide hexaethylene glycol spacers. The aptamer terminates in a hexylamino linker to which two 20-kilodalton monomethoxy polyethylene glycol units are covalently attached via the two amino groups on a lysine residue.

Reagent shall mean N-Hydroxysuccinimide ester of bis-(Methoxypoly(ethylene glycol) MW 20,0000)-modified lysine (mPEG2NHS 40K).

Peglation, with correlative meanings “Pegylated” or to “Pegylate”, means covalent chemical bonding of any poly (ethylene glycol) reagent (including the Reagent and including covalent chemical bonding through linking groups) with or to another material or materials. Such materials include, without limitation, proteins, peptides, oligonucleotides, other biomolecules, small molecules, therapeutic agents (including the Therapeutic Agent), diagnostic agents, imaging agents and detectable labels. Additional materials that may be Pegylated include without limitation, polymers, liposomes, films, chemical separation and purification surfaces, solid supports, metal/metal oxide surfaces and other surfaces such as, by way of example but not limitation, those on implanted devices, and equipment, where a poly (ethylene glycol) reagent (including the Reagent) is covalently chemically bonded to one or more reactive molecules on the surface of such device or equipment. “PEGYLATION” shall include the synthesis, derivatization, characterization, and modification of PEG for such purposes, together with the synthesis, derivatization, characterization, and modification of the raw materials and intermediates for the manufacture of poly (ethylene glycol) reagents (including the Reagent) or products (including the PRODUCT) incorporating such poly (ethylene glycol) reagent by means of covalent chemical bonding, and all methods of making and using each and all of the foregoing.

Enzon Patents shall mean (a) all patent applications owned or controlled by Enzon or affiliates that were affiliates of Enzon as of January 7, 2002 (Enzon affiliates) that pertain to Pegylation and that claim the composition, manufacture, or use of the product that (i) have issued on or before January 7, 2002, or (ii) issue from any patent application included in claue (a) of this definition. The Enzon Patents include those listed but not limited.
US Patent 5,643,575 – Non-antigenic branched polymer conjugates

Field of Use
The  license pertains to certain of proprietary PEGylation technology to develop, manufacture and commercialize particular products that use our proprietary PEGylation reagent linked with the active ingredient in Fovista®.

Fovista® is an anti-PDGF agent administered in combination with anti-vascular endothelial growth factor (anti-VEGF) therapy for the treatment of neovascular age-related macular degeneration (or wet AMD).

IPSCIO Record ID: 328345

License Grant
Generally, by this collaboration, Licensor shall optimize its Existing AsOR Targeted Complex by construction and improvement of plasmid vectors to obtain the required level and duration of Factor VIlI expression from the recombinant Factor VIlI constructs provided by Licensee.

Licensor grants an exclusive license, or in the case of licensed Third Party Patent Rights or Know-How, when permissible, an exclusive sublicense, in the Territory under Licensors Patent Rights, including Licensors rights in any jointly-owned Patent Rights, and Licensors Know How, to conduct the Collaborative Program and to make, use, sell, offer for sale, import, and have made, used, sold, and imported Products for use in the Hemophilia A Field and to each Additional Field(s) upon Licensees exercise of its option(s).

For the License Grant to Licensee Outside the Field(s), for sole inventions and knowhow made by Licensor during the term of and under the Research Program, which are Improvements in the coding and/or non-coding elements for optimizing and/or regulation of gene expression, Licensor grants a world-wide, non-exclusive,
including the right to grant sublicenses, to practice, make, use, sell, import and have practiced, made, used, sold and imported such Improvements for use outside the Field(s).

License Property
Licensor has certain technology regarding the delivery of human genes for use in the prevention and treatment of diseases, states and conditions in humans.

Alternate Ligand-Targeted Complex shall mean a molecular complex comprising a recombinant AsOR ligand or a non-plasma derived ligand such as, but not limited to, a synthetic carbohydrate ligand, said ligand having the ability to bind to the AsOR receptor and which is covalently linked to a polycation and noncovalently bound to DNA.

AsOR shall mean asialoorosomucoid.

Gene shall mean any one of the Factor VIII Gene or the Additional Gene(s), if any.  Factor VIII Gene shall mean cDNA for full-length human factor VIII or an engineered deletion or substitution constructs, including B-domain deleted constructs, hereinafter modified, of human factor VIII.

Additional Gene shall mean full length or truncated cDNA for a specific human blood coagulation factor, other than factor VIII, which the parties mutually agree to add to the Collaborative Program and the Agreement.

Field of Use
The collaboration agreement is for development gene therapy products for the treatment of hemophilia A, a hereditary blood clotting disorder.

Field shall mean any one of the Hemophilia A Field or the Additional Field(s), if any; or shall mean, collectively, the Hemophilia A Field and the Additional Field(s).

Additional Field shall mean, the treatment of any blood coagulation disorder in humans using Gene Delivery technology for targeting one or more Additional Gene into a mammalian cell of a patient.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.